Analysts Point To Editas Medicine Inc (NASDAQ: EDIT) Growth In The Future

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Recently, Yahoo Finance discussed the stock, revealing that Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

As a NASDAQ listed company, EDIT falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Editas Medicine Inc is $747.74M. A total of 2.4 million shares were traded on the day, compared to an average of 1.93M shares.

Insider Activity

Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, EDIT has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 2 BUYs and 11 SELLs from insiders. Insiders purchased 123,067 shares during that period but sold 14,440.

In the most recent transaction, O’Neill Gilmore Neil sold 77,824 shares of EDIT for 9.42 per share on Mar 05. After the transaction, the CEO now owns 327,470 company shares. In a previous transaction on Mar 04, Mei Baisong sold 20,327 shares at 9.42 per share. EDIT shares that SVP, CHIEF MEDICAL OFFICER owns now total 141,543.

Among the insiders who sold shares, Eaton Bruce disposed of 103 shares on Dec 05 at a per-share price of $10.90. This resulted in the EVP, CBO AND CTO holding 74,791 shares of EDIT after the transaction. In another insider transaction, Eaton Bruce sold 695 shares at $8.21 per share on Nov 14. Company shares held by the EVP, CBO AND CTO now total 74,894.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, EDIT has a high of $11.91 and a low of $6.08.

As of this writing, EDIT has an earnings estimate of -$0.66 per share for the current quarter. EPS was calculated based on a consensus of 15 estimates, with a high estimate of -$0.44 per share and a lower estimate of -$1.09. The company reported an EPS of -$0.55 in the last quarter, which was 3.50% higher than expectations of -$0.57.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. EDIT’s latest balance sheet shows that the firm has $499.85M in Cash & Short Term Investments as of fiscal 2021. There were $26.38M in debt and $46.88M in liabilities at the time. Its Book Value Per Share was $4.27, while its Total Shareholder’s Equity was $553.64M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for EDIT is Buy with a score of 3.88.

Most Popular

Related Posts